155 related articles for article (PubMed ID: 28941780)
21. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH).
Sterba M; Popelová O; Simůnek T; Mazurová Y; Potácová A; Adamcová M; Guncová I; Kaiserová H; Palicka V; Ponka P; Gersl V
Toxicology; 2007 Jun; 235(3):150-66. PubMed ID: 17459556
[TBL] [Abstract][Full Text] [Related]
22. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
[TBL] [Abstract][Full Text] [Related]
23. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF
Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725
[TBL] [Abstract][Full Text] [Related]
24. A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage.
Thougaard AV; Langer SW; Hainau B; Grauslund M; Juhl BR; Jensen PB; Sehested M
Toxicology; 2010 Feb; 269(1):67-72. PubMed ID: 20079798
[TBL] [Abstract][Full Text] [Related]
25. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.
Stěrba M; Popelová O; Vávrová A; Jirkovský E; Kovaříková P; Geršl V; Simůnek T
Antioxid Redox Signal; 2013 Mar; 18(8):899-929. PubMed ID: 22794198
[TBL] [Abstract][Full Text] [Related]
26. Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity.
Spagnuolo RD; Recalcati S; Tacchini L; Cairo G
Br J Pharmacol; 2011 May; 163(2):299-312. PubMed ID: 21232037
[TBL] [Abstract][Full Text] [Related]
27. Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo.
Popelová O; Sterba M; Simůnek T; Mazurová Y; Guncová I; Hroch M; Adamcová M; Gersl V
J Pharmacol Exp Ther; 2008 Jul; 326(1):259-69. PubMed ID: 18434588
[TBL] [Abstract][Full Text] [Related]
28. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.
Jirkovský E; Lenčová-Popelová O; Hroch M; Adamcová M; Mazurová Y; Vávrová J; Mičuda S; Šimůnek T; Geršl V; Štěrba M
Toxicology; 2013 Sep; 311(3):191-204. PubMed ID: 23831762
[TBL] [Abstract][Full Text] [Related]
29. The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin.
Wu X; Patel D; Hasinoff BB
J Inorg Biochem; 2004 Nov; 98(11):1818-23. PubMed ID: 15522409
[TBL] [Abstract][Full Text] [Related]
30. Dexrazoxane provided moderate protection in a catecholamine model of severe cardiotoxicity.
Zatloukalová L; Filipský T; Mladěnka P; Semecký V; Macáková K; Holečková M; Vávrová J; Palicka V; Hrdina R
Can J Physiol Pharmacol; 2012 Apr; 90(4):473-84. PubMed ID: 22439652
[TBL] [Abstract][Full Text] [Related]
31. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.
Hasinoff BB; Hellmann K; Herman EH; Ferrans VJ
Curr Med Chem; 1998 Feb; 5(1):1-28. PubMed ID: 9481032
[TBL] [Abstract][Full Text] [Related]
32. Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity.
Hašková P; Koubková L; Vávrová A; Macková E; Hrušková K; Kovaříková P; Vávrová K; Simůnek T
Toxicology; 2011 Nov; 289(2-3):122-31. PubMed ID: 21864640
[TBL] [Abstract][Full Text] [Related]
33. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
Xu X; Sutak R; Richardson DR
Mol Pharmacol; 2008 Mar; 73(3):833-44. PubMed ID: 18029550
[TBL] [Abstract][Full Text] [Related]
34. The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity.
Kwok JC; Richardson DR
Redox Rep; 2000; 5(6):317-24. PubMed ID: 11140743
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of the Cardioprotective Drug Dexrazoxane and Its Active Metabolite ADR-925 with Focus on Cardiomyocytes and the Heart.
Jirkovský E; Jirkovská A; Bureš J; Chládek J; Lenčová O; Stariat J; Pokorná Z; Karabanovich G; Roh J; Brázdová P; Šimůnek T; Kovaříková P; Štěrba M
J Pharmacol Exp Ther; 2018 Mar; 364(3):433-446. PubMed ID: 29273587
[TBL] [Abstract][Full Text] [Related]
36. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity.
Sterba M; Popelová O; Simunek T; Mazurová Y; Potácová A; Adamcová M; Kaiserová H; Ponka P; Gersl V
J Pharmacol Exp Ther; 2006 Dec; 319(3):1336-47. PubMed ID: 17003229
[TBL] [Abstract][Full Text] [Related]
37. The iron chelator Dp44mT does not protect myocytes against doxorubicin.
Hasinoff BB; Patel D
J Inorg Biochem; 2009 Jul; 103(7):1093-101. PubMed ID: 19535146
[TBL] [Abstract][Full Text] [Related]
38. Resveratrol significantly improves cell survival in comparison to dexrazoxane and carvedilol in a h9c2 model of doxorubicin induced cardiotoxicity.
Monahan DS; Flaherty E; Hameed A; Duffy GP
Biomed Pharmacother; 2021 Aug; 140():111702. PubMed ID: 34015579
[TBL] [Abstract][Full Text] [Related]
39. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
Jones RL
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
[TBL] [Abstract][Full Text] [Related]
40. Treatment of anthracycline extravasation with dexrazoxane.
Langer SW; Sehested M; Jensen PB
Clin Cancer Res; 2000 Sep; 6(9):3680-6. PubMed ID: 10999761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]